Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2015.08.04
- VernacularTitle:NSCLC携带EGFR少见突变分析及EGFR-TKIs疗效初步观察
- Author:
YANG XUE
1
;
CHEN HANXIAO
;
ZHANG HONG
;
DUAN JIANCHUN
;
AN TONGTONG
;
ZHAO JUN
;
ZHUO MINGLEI
;
WU MEINA
;
WANG JIE
Author Information
1. 100142北京，北京大学肿瘤医院暨北京市肿瘤防治研究所胸部肿瘤内一科，恶性肿瘤发病机制及转化研究教育部重点实验室
- Keywords:
Lung neoplasms;
EGFR;
Uncommon mutation;
Target therapy
- From:
Chinese Journal of Lung Cancer
2015;(8):493-499
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Epidermal growth factor receptor (EGFR) mutations occur more frequently in non-small cell lung cancer (NSCLC) of women, never smokers, Asian population and those with adenocarcinoma. Short in-frame deletion in exon 19 and L858R substitution are the most common mutations, which are closely associated with EGFR tyrosine kinase inhibitors (TKIs) treatment response. However, the therapeutic effects of EGFR-TKIs on NSCLC with uncom-monEGFR mutation subtypes remain unclear. hTe aim of this study is to investigate the clinicopathologic feature of uncom-monEGFR mutations and the outcomes of these patients.Methods Twenty-four patients that harbored uncommonEGFR mutations were included in this study. Clinicopathologic features of uncommonEGFR mutations and the outcomes of these patients were analyzed.Results Of the 24 patients, 13 received EGFR-TKIs treatment. hTe response rate of EGFR-TKIs treat-ment was 46.1%, and the median progression-free survival (PFS) was 7.4 months. Mutations on S768I and L861Q composed a major part (8 of 24) of uncommon mutations.Conclusions UncommonEGFR mutations constituted a unique part of the whole group ofEGFR mutations. hTeir composition and sensitivity to EGFR-TKIs were heterogeneous, which requires further assessment in a prospective study.
